Aquestive Therapeutics (AQST) Treasury Shares (2018 - 2026)

Aquestive Therapeutics' Treasury Shares history runs 9 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• On a quarterly basis, Treasury Shares fell 14.0% year-over-year to $2.8 million in Q1 2026; TTM through Mar 2026 was $2.8 million, a 14.0% decrease from a year earlier, with the FY2025 full-year figure at $2.7 million, up 148.06% from the prior year.
• Treasury Shares climbed to $2.8 million in Q1 2026 per AQST's latest filing, from $2.7 million in the prior quarter.
• Across five years, Treasury Shares topped out at $3.3 million in Q1 2025 and bottomed at $162000.0 in Q4 2022.
• The 5-year median for Treasury Shares is $1.8 million (2023), against an average of $1.7 million.
• Across the five-year window, Treasury Shares surged 2025.0% in 2022 and slumped 35.09% in 2024, its largest moves.
• Year by year, Treasury Shares stood at $162000.0 in 2022, then soared by 722.22% to $1.3 million in 2023, then decreased by 18.77% to $1.1 million in 2024, then surged by 148.06% to $2.7 million in 2025, then increased by 5.77% to $2.8 million in 2026.
• Per Business Quant, the three latest AQST Treasury Shares figures stand at $2.8 million (Q1 2026), $2.7 million (Q4 2025), and $1.8 million (Q3 2025).